Home   |   Research & Knowledge   |   Contact   |   Careers   |   FAQs
Gainers & Losers
Weekly Gainers
Weekly Losers
New Highs & New Lows
52 Week Highs
52 Week Lows
Advance and Decline
Bulk Deals
Block Deals
Detailed Quotes
Company Background
Board Of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Prices
Company News
Directors Reports
Share Holding Pattern
Quoted & Unquoted Investment
Equity History
Foreign Market
Pre Session
Mid Session
End Session
FII Activities
MF Activities
Company News
Dr Reddys settles litigation related to its generic buprenorphine and naloxone sublingual film
(24 Jun 2022)
Dr Reddys Laboratories has entered into a Settlement Agreement with Indivior Inc. and Indivior UK and Aquestive Therapeutics, Inc. (Aquestive). Pursuant to the agreement, the Company will receive payments totalling USD 72 million by 31 March 2024. The said agreement resolves all claims between the parties relating to the Company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's and Aquestive's patent infringement allegations and the Company's antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.
Back Top
Home   |   The Company   |   Portfolio Management   |   Research & Knowledge   |   Privacy & Security
© 2011, Equity Intelligence Pvt. Ltd.       Developed & powered by CMOTS Infotech (ISO 9001:2015 certified)